Proxalutamide Reduces Hospitalization Rate in Mild-to-Moderate COVID-19 Female Patients: A Randomized Double-Blinded Placebo-Controlled Trial

    July 2021 in “ medRxiv (Cold Spring Harbor Laboratory) ”
    Flavio Cadegiani, Ricardo Ariel Zimerman, Daniel Fonseca … Andy Goren

    Preprint — not peer reviewed. This was posted to a preprint server or data repository. It has not been through a journal's review process, and its findings may change or not hold up.

    Studysummary This study found that proxalutamide treatment significantly reduced 30-day hospitalization rates in women with mild-to-moderate COVID-19 compared to placebo, with no safety issues identified.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on medrxiv.org →
    Discuss this study in the Community →

    Research cited in this study 11

    1. Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial Frontiers in Medicine · 2021
    2. Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial Cureus · 2021
    3. Anti-Androgens May Protect Against Severe COVID-19 Outcomes: Results From a Prospective Cohort Study of 77 Hospitalized Men Journal of The European Academy of Dermatology and Venereology · 2021
    4. 5-Alpha-Reductase Inhibitors Are Associated With Reduced Frequency of COVID-19 Symptoms in Males With Androgenetic Alopecia Journal of The European Academy of Dermatology and Venereology · 2020
    5. Clinical Symptoms of Hyperandrogenic Women Diagnosed with COVID-19 Journal of the European Academy of Dermatology and Venereology · 2020
    6. Repurposing Existing Drugs for COVID-19: An Endocrinology Perspective BMC Endocrine Disorders · 2020
    7. Androgenetic Alopecia in COVID-19: Comparison to Age-Matched Epidemiologic Studies and Hospital Outcomes With or Without the Gabrin Sign Journal of The American Academy of Dermatology · 2020
    8. Polycystic Ovary Syndrome (PCOS) and COVID-19: An Overlooked Female Patient Population at Potentially Higher Risk During the COVID-19 Pandemic BMC Medicine · 2020
    9. Androgenetic Alopecia Present in the Majority of Patients Hospitalized with COVID-19: The 'Gabrin Sign' Journal of The American Academy of Dermatology · 2020
    10. Racial Variations in COVID-19 Deaths May Be Due to Androgen Receptor Genetic Variants Associated with Prostate Cancer and Androgenetic Alopecia. Are Anti-Androgens a Potential Treatment for COVID-19? Journal of Cosmetic Dermatology · 2020
    11. A Preliminary Observation: Male Pattern Hair Loss Among Hospitalized COVID-19 Patients in Spain – A Potential Clue to the Role of Androgens in COVID-19 Severity Journal of Cosmetic Dermatology · 2020